How can we achieve universal access to low-cost treatment for HIV?

How can we achieve universal access to low-cost treatment for HIV?

Mass production of low-cost antiretrovirals (ARVs) has already allowed over 17 million individuals to access treatment for HIV infection, mainly in low-income countries. It is possible to manufacture combination ARVs for $110 per person-year, using tenofovir (TDF), lamivudine (3TC) and efavirenz (EF...

Full description

Bibliographic Details
Main Authors: Andrew M. Hill, Anton L. Pozniak
Format: Article
Language:English
Published: Elsevier 2016-10-01
Series:Journal of Virus Eradication
Subjects:
antiretrovirals
nucleoside analogues
protease inhibitors
non-nucleosides
integrase strand inhibitors
health economics
Online Access:http://www.sciencedirect.com/science/article/pii/S2055664020308712

Internet

http://www.sciencedirect.com/science/article/pii/S2055664020308712

Similar Items